Britannia Life Sciences（BLAB）株式概要ブリタニア・ライフサイエンス社は、主に化粧品、消費者向けパッケージ商品、家庭用品、栄養補助食品業界向けに、製品試験、安全性評価、コンプライアンスサービスを英国内外で提供している。 詳細BLAB ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性4/6配当金0/6報酬株価収益率（ 1.8 x） Canadian市場（ 16.5 x）を下回っています。今年は黒字化を達成 リスク分析収益が 100 万ドル未満 ( CA$158K )高いレベルの非現金収入 意味のある時価総額がありません ( CA$15M )すべてのリスクチェックを見るBLAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.091.5k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-10m8m2016201920222025202620282031Revenue CA$13.2kEarnings CA$665.4kAdvancedSet Fair ValueView all narrativesBritannia Life Sciences Inc. 競合他社Caldwell Partners InternationalSymbol: TSX:CWLMarket cap: CA$26.5mDGA Spólka AkcyjnaSymbol: WSE:DGAMarket cap: zł27.3mSSC Security ServicesSymbol: TSXV:SECUMarket cap: CA$36.5mCatalyst Media GroupSymbol: AIM:CMXMarket cap: UK£8.9m価格と性能株価の高値、安値、推移の概要Britannia Life Sciences過去の株価現在の株価CA$0.0952週高値CA$0.1452週安値CA$0.06ベータ-0.0721ヶ月の変化0%3ヶ月変化-10.00%1年変化28.57%3年間の変化-28.00%5年間の変化n/aIPOからの変化-66.67%最新ニュースNew Risk • Apr 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (185% accrual ratio). Revenue is less than US$1m (CA$158k revenue, or US$114k). Market cap is less than US$10m (CA$13.8m market cap, or US$9.98m).Reported Earnings • Mar 08Third quarter 2026 earnings released: EPS: CA$0.067 (vs CA$0.002 loss in 3Q 2025)Third quarter 2026 results: EPS: CA$0.067 (up from CA$0.002 loss in 3Q 2025). Net income: CA$10.8m (up CA$11.2m from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.分析記事 • Jan 27Does Britannia Life Sciences (CSE:BLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...お知らせ • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.Reported Earnings • Dec 02Second quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.01 loss in 2Q 2025)Second quarter 2026 results: CA$0.003 loss per share (improved from CA$0.01 loss in 2Q 2025). Net loss: CA$411.3k (loss narrowed 73% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.最新情報をもっと見るRecent updatesNew Risk • Apr 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (185% accrual ratio). Revenue is less than US$1m (CA$158k revenue, or US$114k). Market cap is less than US$10m (CA$13.8m market cap, or US$9.98m).Reported Earnings • Mar 08Third quarter 2026 earnings released: EPS: CA$0.067 (vs CA$0.002 loss in 3Q 2025)Third quarter 2026 results: EPS: CA$0.067 (up from CA$0.002 loss in 3Q 2025). Net income: CA$10.8m (up CA$11.2m from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.分析記事 • Jan 27Does Britannia Life Sciences (CSE:BLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...お知らせ • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.Reported Earnings • Dec 02Second quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.01 loss in 2Q 2025)Second quarter 2026 results: CA$0.003 loss per share (improved from CA$0.01 loss in 2Q 2025). Net loss: CA$411.3k (loss narrowed 73% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31First quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.004 loss per share (improved from CA$0.005 loss in 1Q 2025). Net loss: CA$690.9k (loss narrowed 6.4% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 31Full year 2025 earnings released: CA$0.029 loss per share (vs CA$0.029 loss in FY 2024)Full year 2025 results: CA$0.029 loss per share (in line with FY 2024). Net loss: CA$4.67m (loss narrowed 2.0% from FY 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.Buy Or Sell Opportunity • Jul 22Now 53% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CA$0.085. The fair value is estimated to be CA$0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jul 04Now 29% overvaluedOver the last 90 days, the stock has fallen 6.7% to CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jun 12Now 22% overvaluedOver the last 90 days, the stock has fallen 13% to CA$0.065. The fair value is estimated to be CA$0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • May 21Now 29% overvaluedThe stock has been flat over the last 90 days, currently trading at CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • May 01Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to CA$0.065. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Apr 14Now 29% overvaluedOver the last 90 days, the stock has fallen 13% to CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Mar 06Now 39% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to CA$0.065. The fair value is estimated to be CA$0.047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Mar 04Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.003 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.003 profit in 3Q 2024). Revenue: CA$1.74m (down 4.0% from 3Q 2024). Net loss: CA$136.9k (down 126% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.分析記事 • Feb 06Is Britannia Life Sciences (CSE:BLAB) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Feb 01New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: CA$7.3m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (53% average weekly change). Earnings have declined by 0.07% per year over the past 5 years. Market cap is less than US$10m (CA$11.4m market cap, or US$7.81m). Minor Risk Revenue is less than US$5m (CA$7.3m revenue, or US$5.0m).お知らせ • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.Board Change • Jan 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 0.07% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Earnings have declined by 0.07% per year over the past 5 years. Market cap is less than US$10m (CA$8.11m market cap, or US$5.79m).Reported Earnings • Dec 01Second quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.004 profit in 2Q 2024)Second quarter 2025 results: CA$0.007 loss per share (down from CA$0.004 profit in 2Q 2024). Revenue: CA$1.96m (down 5.7% from 2Q 2024). Net loss: CA$1.19m (down 265% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Oct 11Britannia Life Sciences Inc. announced that it expects to receive CAD 0.00255 million in fundingBritannia Life Sciences Inc. announced a private placement to issue 2% Unsecured Convertible Debenture at principal amount of CAD 2,550 for gross proceeds of CAD 2,550 on October 10, 2024. Under the terms of the first offering, the company will issue CAD 1,275 principal amount 2% unsecured debentures that will have a two-year term and be convertible into common shares of BMS . Pursuant to the second offering, BMS will directly issue CAD 1,275 principal amount 2% unsecured convertible debentures due two years from closing to investors. Each debenture will automatically convert into 100 common shares of BMS, representing a conversion price of CAD 12.75 per common share.お知らせ • Sep 17Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024.Board Change • Sep 16High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Full year 2024 earnings released: CA$0.029 loss per share (vs CA$0.031 profit in FY 2023)Full year 2024 results: CA$0.029 loss per share (down from CA$0.031 profit in FY 2023). Revenue: CA$7.57m (up 18% from FY 2023). Net loss: CA$4.77m (down 194% from profit in FY 2023).お知らせ • Jul 23Britannia Life Sciences Inc. announced that it has received CAD 0.932 million in fundingOn July 22, 2024, Britannia Life Sciences Inc. closed the transaction. The company issued 10% 932 unsecured non convertible subordinated debenture units at an issue price of CAD 1,000 per unit for the gross proceeds of CAD 932,000. The transaction included participation from insiders for CAD 260,000. The company paid finder's fees in the amount of CAD 3,500 in connection with the private placement. The debentures will pay interest at a rate of 10% per annum, paid annually in arrears, and have a maturity date of 12 months from the date of issue, subject to extension at the company's option for an additional 12 months.Buy Or Sell Opportunity • Mar 12Now 28% undervaluedThe stock has been flat over the last 90 days, currently trading at CA$0.07. The fair value is estimated to be CA$0.098, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.003 (up from CA$0 in 3Q 2023). Revenue: CA$1.81m (up 9.6% from 3Q 2023). Net income: CA$535.3k (up CA$589.7k from 3Q 2023). Profit margin: 30% (up from net loss in 3Q 2023).分析記事 • Mar 01Britannia Life Sciences (CSE:BLAB) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...New Risk • Dec 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (22% average weekly change). Market cap is less than US$10m (CA$13.0m market cap, or US$9.55m). Minor Risk Large one-off items impacting financial results.お知らせ • Dec 01Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million.Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million on November 22, 2023. The acquisition increases the Company's ownership interest in ADSL to 72%.Britannia Life Sciences Inc. (CNSX:BLAB) completed the acquisition of additional 2% stake in Advanced Development & Safety Laboratories Limited on November 22, 2023.Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.007 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.004 (down from CA$0.007 in 2Q 2023). Revenue: CA$2.07m (up 30% from 2Q 2023). Net income: CA$724.2k (down 33% from 2Q 2023). Profit margin: 35% (down from 68% in 2Q 2023).分析記事 • Nov 14Britannia Life Sciences (CSE:BLAB) Might Have The Makings Of A Multi-BaggerTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Board Change • Sep 09High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 02New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$6.4m revenue, or US$4.8m). Market cap is less than US$100m (CA$16.2m market cap, or US$12.2m).Reported Earnings • Aug 01Full year 2023 earnings released: EPS: CA$0.031 (vs CA$0.14 loss in FY 2022)Full year 2023 results: EPS: CA$0.031 (up from CA$0.14 loss in FY 2022). Revenue: CA$6.40m (down 12% from FY 2022). Net income: CA$5.08m (up CA$20.5m from FY 2022). Profit margin: 79% (up from net loss in FY 2022).お知らせ • Jul 29Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023.New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 6.8% over the past year. Market cap is less than US$10m (CA$13.0m market cap, or US$9.83m). Minor Risk Revenue is less than US$5m (CA$6.5m revenue, or US$4.9m).Buying Opportunity • Jul 25Now 31% undervalued after recent price dropOver the last 90 days, the stock is down 5.9%. The fair value is estimated to be CA$0.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.Buying Opportunity • Apr 25Now 25% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be CA$0.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.分析記事 • Apr 19Returns At Britannia Life Sciences (CSE:BLAB) Appear To Be Weighed DownThere are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...Buying Opportunity • Mar 13Now 26% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be CA$0.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.分析記事 • Mar 13A Look At The Fair Value Of Britannia Life Sciences Inc. (CSE:BLAB)Key Insights Britannia Life Sciences' estimated fair value is CA$0.13 based on 2 Stage Free Cash Flow to Equity Current...Reported Earnings • Mar 02Third quarter 2023 earnings released: EPS: CA$0 (vs CA$0.083 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0 (improved from CA$0.083 loss in 3Q 2022). Revenue: CA$1.65m (flat on 3Q 2022). Net loss: CA$54.3k (loss narrowed 100% from 3Q 2022).Reported Earnings • Dec 01Second quarter 2023 earnings released: EPS: CA$0.007 (vs CA$0.01 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.007 (up from CA$0.01 loss in 2Q 2022). Revenue: CA$1.59m (down 17% from 2Q 2022). Net income: CA$1.08m (up CA$1.88m from 2Q 2022). Profit margin: 68% (up from net loss in 2Q 2022).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 15Britannia Life Sciences Inc., Annual General Meeting, Dec 15, 2022Britannia Life Sciences Inc., Annual General Meeting, Dec 15, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 09Britannia Life Sciences Inc. (CNSX:BLAB) entered into an agreement to acquire additional 10% stake in Advanced Development & Safety Laboratories Limited.Britannia Life Sciences Inc. (CNSX:BLAB) entered into an agreement to acquire additional 10% stake in Advanced Development & Safety Laboratories Limited on April 7, 2022. Upon completion of the Additional ADSL Purchase, Britannia will own a 70% interest in ADSL, Britannia's largest operating subsidiary. Gowling WLG (UK) LLP and Bennett Jones LLP acted as legal advisor to Britannia Life Sciences Inc.Recent Insider Transactions • Dec 04Director & CEO recently bought CA$55k worth of stockOn the 26th of November, Peter Shippen bought around 342k shares on-market at roughly CA$0.16 per share. In the last 3 months, they made an even bigger purchase worth CA$434k. Peter has been a buyer over the last 12 months, purchasing a net total of CA$488k worth in shares.Recent Insider Transactions • Nov 27Director & CEO recently bought CA$434k worth of stockOn the 18th of November, Peter Shippen bought around 2m shares on-market at roughly CA$0.28 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元BLABCA Professional ServicesCA 市場7D5.9%4.0%1.6%1Y28.6%-56.6%32.9%株主還元を見る業界別リターン: BLAB過去 1 年間で-56.6 % の収益を上げたCanadian Professional Services業界を上回りました。リターン対市場: BLABは、過去 1 年間で32.9 % のリターンを上げたCanadian市場を下回りました。価格変動Is BLAB's price volatile compared to industry and market?BLAB volatilityBLAB Average Weekly Movement9.1%Professional Services Industry Average Movement7.4%Market Average Movement10.2%10% most volatile stocks in CA Market17.8%10% least volatile stocks in CA Market3.9%安定した株価: BLAB 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BLABの 週次ボラティリティ は、過去 1 年間で18%から9%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aPete Shippenbritannia.lifeブリタニア・ライフサイエンシズ社は、主に化粧品、消費者向けパッケージ商品、家庭用品、栄養補助食品業界向けに、製品試験、安全性評価、コンプライアンス・サービスを英国内外で提供している。本社はカナダのトロント。もっと見るBritannia Life Sciences Inc. 基礎のまとめBritannia Life Sciences の収益と売上を時価総額と比較するとどうか。BLAB 基礎統計学時価総額CA$14.60m収益（TTM）CA$7.93m売上高(TTM)CA$157.68k1.8xPER（株価収益率92.6xP/SレシオBLAB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BLAB 損益計算書（TTM）収益CA$157.68k売上原価CA$344.83k売上総利益-CA$187.15kその他の費用-CA$8.12m収益CA$7.93m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.049グロス・マージン-118.69%純利益率5,029.14%有利子負債／自己資本比率0.7%BLAB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:50終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Britannia Life Sciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (185% accrual ratio). Revenue is less than US$1m (CA$158k revenue, or US$114k). Market cap is less than US$10m (CA$13.8m market cap, or US$9.98m).
Reported Earnings • Mar 08Third quarter 2026 earnings released: EPS: CA$0.067 (vs CA$0.002 loss in 3Q 2025)Third quarter 2026 results: EPS: CA$0.067 (up from CA$0.002 loss in 3Q 2025). Net income: CA$10.8m (up CA$11.2m from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
分析記事 • Jan 27Does Britannia Life Sciences (CSE:BLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
お知らせ • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.
Reported Earnings • Dec 02Second quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.01 loss in 2Q 2025)Second quarter 2026 results: CA$0.003 loss per share (improved from CA$0.01 loss in 2Q 2025). Net loss: CA$411.3k (loss narrowed 73% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.
New Risk • Apr 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (185% accrual ratio). Revenue is less than US$1m (CA$158k revenue, or US$114k). Market cap is less than US$10m (CA$13.8m market cap, or US$9.98m).
Reported Earnings • Mar 08Third quarter 2026 earnings released: EPS: CA$0.067 (vs CA$0.002 loss in 3Q 2025)Third quarter 2026 results: EPS: CA$0.067 (up from CA$0.002 loss in 3Q 2025). Net income: CA$10.8m (up CA$11.2m from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
分析記事 • Jan 27Does Britannia Life Sciences (CSE:BLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
お知らせ • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.
Reported Earnings • Dec 02Second quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.01 loss in 2Q 2025)Second quarter 2026 results: CA$0.003 loss per share (improved from CA$0.01 loss in 2Q 2025). Net loss: CA$411.3k (loss narrowed 73% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.
Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31First quarter 2026 earnings released: CA$0.004 loss per share (vs CA$0.005 loss in 1Q 2025)First quarter 2026 results: CA$0.004 loss per share (improved from CA$0.005 loss in 1Q 2025). Net loss: CA$690.9k (loss narrowed 6.4% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 31Full year 2025 earnings released: CA$0.029 loss per share (vs CA$0.029 loss in FY 2024)Full year 2025 results: CA$0.029 loss per share (in line with FY 2024). Net loss: CA$4.67m (loss narrowed 2.0% from FY 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.
Buy Or Sell Opportunity • Jul 22Now 53% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to CA$0.085. The fair value is estimated to be CA$0.055, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jul 04Now 29% overvaluedOver the last 90 days, the stock has fallen 6.7% to CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jun 12Now 22% overvaluedOver the last 90 days, the stock has fallen 13% to CA$0.065. The fair value is estimated to be CA$0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • May 21Now 29% overvaluedThe stock has been flat over the last 90 days, currently trading at CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • May 01Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to CA$0.065. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Apr 14Now 29% overvaluedOver the last 90 days, the stock has fallen 13% to CA$0.07. The fair value is estimated to be CA$0.054, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Mar 06Now 39% overvalued after recent price riseOver the last 90 days, the stock has risen 30% to CA$0.065. The fair value is estimated to be CA$0.047, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Mar 04Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.003 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.003 profit in 3Q 2024). Revenue: CA$1.74m (down 4.0% from 3Q 2024). Net loss: CA$136.9k (down 126% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
分析記事 • Feb 06Is Britannia Life Sciences (CSE:BLAB) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Feb 01New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: CA$7.3m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (53% average weekly change). Earnings have declined by 0.07% per year over the past 5 years. Market cap is less than US$10m (CA$11.4m market cap, or US$7.81m). Minor Risk Revenue is less than US$5m (CA$7.3m revenue, or US$5.0m).
お知らせ • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.
Board Change • Jan 07Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 0.07% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Earnings have declined by 0.07% per year over the past 5 years. Market cap is less than US$10m (CA$8.11m market cap, or US$5.79m).
Reported Earnings • Dec 01Second quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.004 profit in 2Q 2024)Second quarter 2025 results: CA$0.007 loss per share (down from CA$0.004 profit in 2Q 2024). Revenue: CA$1.96m (down 5.7% from 2Q 2024). Net loss: CA$1.19m (down 265% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Oct 11Britannia Life Sciences Inc. announced that it expects to receive CAD 0.00255 million in fundingBritannia Life Sciences Inc. announced a private placement to issue 2% Unsecured Convertible Debenture at principal amount of CAD 2,550 for gross proceeds of CAD 2,550 on October 10, 2024. Under the terms of the first offering, the company will issue CAD 1,275 principal amount 2% unsecured debentures that will have a two-year term and be convertible into common shares of BMS . Pursuant to the second offering, BMS will directly issue CAD 1,275 principal amount 2% unsecured convertible debentures due two years from closing to investors. Each debenture will automatically convert into 100 common shares of BMS, representing a conversion price of CAD 12.75 per common share.
お知らせ • Sep 17Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024.
Board Change • Sep 16High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Full year 2024 earnings released: CA$0.029 loss per share (vs CA$0.031 profit in FY 2023)Full year 2024 results: CA$0.029 loss per share (down from CA$0.031 profit in FY 2023). Revenue: CA$7.57m (up 18% from FY 2023). Net loss: CA$4.77m (down 194% from profit in FY 2023).
お知らせ • Jul 23Britannia Life Sciences Inc. announced that it has received CAD 0.932 million in fundingOn July 22, 2024, Britannia Life Sciences Inc. closed the transaction. The company issued 10% 932 unsecured non convertible subordinated debenture units at an issue price of CAD 1,000 per unit for the gross proceeds of CAD 932,000. The transaction included participation from insiders for CAD 260,000. The company paid finder's fees in the amount of CAD 3,500 in connection with the private placement. The debentures will pay interest at a rate of 10% per annum, paid annually in arrears, and have a maturity date of 12 months from the date of issue, subject to extension at the company's option for an additional 12 months.
Buy Or Sell Opportunity • Mar 12Now 28% undervaluedThe stock has been flat over the last 90 days, currently trading at CA$0.07. The fair value is estimated to be CA$0.098, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.003 (up from CA$0 in 3Q 2023). Revenue: CA$1.81m (up 9.6% from 3Q 2023). Net income: CA$535.3k (up CA$589.7k from 3Q 2023). Profit margin: 30% (up from net loss in 3Q 2023).
分析記事 • Mar 01Britannia Life Sciences (CSE:BLAB) Shareholders Will Want The ROCE Trajectory To ContinueIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
New Risk • Dec 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (22% average weekly change). Market cap is less than US$10m (CA$13.0m market cap, or US$9.55m). Minor Risk Large one-off items impacting financial results.
お知らせ • Dec 01Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million.Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million on November 22, 2023. The acquisition increases the Company's ownership interest in ADSL to 72%.Britannia Life Sciences Inc. (CNSX:BLAB) completed the acquisition of additional 2% stake in Advanced Development & Safety Laboratories Limited on November 22, 2023.
Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.007 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.004 (down from CA$0.007 in 2Q 2023). Revenue: CA$2.07m (up 30% from 2Q 2023). Net income: CA$724.2k (down 33% from 2Q 2023). Profit margin: 35% (down from 68% in 2Q 2023).
分析記事 • Nov 14Britannia Life Sciences (CSE:BLAB) Might Have The Makings Of A Multi-BaggerTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Board Change • Sep 09High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 02New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$6.4m revenue, or US$4.8m). Market cap is less than US$100m (CA$16.2m market cap, or US$12.2m).
Reported Earnings • Aug 01Full year 2023 earnings released: EPS: CA$0.031 (vs CA$0.14 loss in FY 2022)Full year 2023 results: EPS: CA$0.031 (up from CA$0.14 loss in FY 2022). Revenue: CA$6.40m (down 12% from FY 2022). Net income: CA$5.08m (up CA$20.5m from FY 2022). Profit margin: 79% (up from net loss in FY 2022).
お知らせ • Jul 29Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023.
New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.0m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 6.8% over the past year. Market cap is less than US$10m (CA$13.0m market cap, or US$9.83m). Minor Risk Revenue is less than US$5m (CA$6.5m revenue, or US$4.9m).
Buying Opportunity • Jul 25Now 31% undervalued after recent price dropOver the last 90 days, the stock is down 5.9%. The fair value is estimated to be CA$0.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
Buying Opportunity • Apr 25Now 25% undervaluedOver the last 90 days, the stock is up 36%. The fair value is estimated to be CA$0.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
分析記事 • Apr 19Returns At Britannia Life Sciences (CSE:BLAB) Appear To Be Weighed DownThere are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...
Buying Opportunity • Mar 13Now 26% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be CA$0.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
分析記事 • Mar 13A Look At The Fair Value Of Britannia Life Sciences Inc. (CSE:BLAB)Key Insights Britannia Life Sciences' estimated fair value is CA$0.13 based on 2 Stage Free Cash Flow to Equity Current...
Reported Earnings • Mar 02Third quarter 2023 earnings released: EPS: CA$0 (vs CA$0.083 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0 (improved from CA$0.083 loss in 3Q 2022). Revenue: CA$1.65m (flat on 3Q 2022). Net loss: CA$54.3k (loss narrowed 100% from 3Q 2022).
Reported Earnings • Dec 01Second quarter 2023 earnings released: EPS: CA$0.007 (vs CA$0.01 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.007 (up from CA$0.01 loss in 2Q 2022). Revenue: CA$1.59m (down 17% from 2Q 2022). Net income: CA$1.08m (up CA$1.88m from 2Q 2022). Profit margin: 68% (up from net loss in 2Q 2022).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 15Britannia Life Sciences Inc., Annual General Meeting, Dec 15, 2022Britannia Life Sciences Inc., Annual General Meeting, Dec 15, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 09Britannia Life Sciences Inc. (CNSX:BLAB) entered into an agreement to acquire additional 10% stake in Advanced Development & Safety Laboratories Limited.Britannia Life Sciences Inc. (CNSX:BLAB) entered into an agreement to acquire additional 10% stake in Advanced Development & Safety Laboratories Limited on April 7, 2022. Upon completion of the Additional ADSL Purchase, Britannia will own a 70% interest in ADSL, Britannia's largest operating subsidiary. Gowling WLG (UK) LLP and Bennett Jones LLP acted as legal advisor to Britannia Life Sciences Inc.
Recent Insider Transactions • Dec 04Director & CEO recently bought CA$55k worth of stockOn the 26th of November, Peter Shippen bought around 342k shares on-market at roughly CA$0.16 per share. In the last 3 months, they made an even bigger purchase worth CA$434k. Peter has been a buyer over the last 12 months, purchasing a net total of CA$488k worth in shares.
Recent Insider Transactions • Nov 27Director & CEO recently bought CA$434k worth of stockOn the 18th of November, Peter Shippen bought around 2m shares on-market at roughly CA$0.28 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
